glp 1 glucagon dual receptor agonist GIP/GLP-1 agonists: New advances for treating type-2 diabetes Frontiers | GLP−1 receptor agonists
Description
For instance, retrospective analyses have suggested potential associations with thyroid cancer risk during long-term use [4], whereas studies of pancreatic cancer have yielded contrasting results [6,7,8]
BYETTA (exenatide) injection
2015, p
A non-significant reduction in coronary plaque volume, decrease in liquid plaque volume, and a decrease in non-HDL cholesterol was observed in the sitagliptin group [81]
However, iGlarLixi patients had more gastrointestinal-related adverse, primarily nausea (16.9% vs
Based on the above mechanisms of cells, GLP-1RA treatment exerts favorable effects on hyperglycemia (Figure 2)
